Navigation Links
Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
Date:3/19/2008

ced capabilities including fixed-beam IMRT and stereotactic treatments. No other company offers this level of options for customizing treatments according to each patient's specific needs on one treatment machine."

"Varian is committed to joining forces with clinicians on the development of better treatments for cancer patients and RapidArc demonstrates the success of these collaborations. It's a win for everybody but, most importantly, it's a win for the patients."

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,600 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit http://www.varian.com/.

Forward Looking Statements

Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters, including, but not limited to, statements using the terms "can" and "makes it possible to" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to,
'/>"/>

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Specialized Care for Ovarian Cancer Improves Outcomes
2. Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers
3. Advanced-stage ovarian cancer patients with BRCA live longer, may respond better to treatment
4. Gleevec May Disrupt Ovarian Function
5. U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
6. Researchers identify and shut down protein that fuels ovarian cancer
7. Varian Medical Systems Announces Symposia on RapidArc Technology for Faster, More Precise Radiotherapy Treatments
8. Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
9. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
10. Yale test detects early stage ovarian cancer with 99 percent accuracy
11. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2008)...tering recipes to cut fat, salt a quick fix withou..., Nov. 22 (HealthDay News) -- You can eat healthie...ng good food choices, say experts with the Texas A... reduce the sugar, fat or salt content of almost a...in taste, nutrition specialist Mary Bielamowicz sa...
(Date:11/21/2008)...nding may lead to new therapies for preterm labor ...Researchers say they,ve found the switch that acti...hildbirth, a finding that may lead to therapies fo...ormally binds the protein IP on the surface of the...nactive during pregnancy. , But researchers fr...
(Date:11/21/2008)...OUSTON(Nov. 21, 2008)The University of Texas Healt...ram, Training Excellence in Aging Studies (TEXAS),...ough a prestigious $2 million award from the Donal...hing funds., "This will allow us to teach geriatr...unior medical student to practicing physicians. Wi...
(Date:11/21/2008)...LINGTON, Va., Nov. 21 T...ased the following statement today from,GPhA Pres...l Trade Commission,(FTC) roundtable on "Emerging ... "The mere fact that the FTC is conducting thi...hind ensuring that consumers have access to safe a...
Breaking Medicine News(10 mins):Health News:Substitutions Make Holiday Fare Healthier 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2
...nding every waking hour in front of the computer s...in the new year is out of the window and no sooner...While you recline and read this piece, the America...nactive’ trend is disastrous for your heart. ‘Get ...
...h minimal side effects - Scientists of a consortiu... Greece, has been awarded a grant from the Europea...very and validation of new therapeutic strategies ...-named Apotherapy, will develop methods to activat...
... think this piece of news is science fiction; now,...s with the desired characteristics- hair color, ey... advance. The Abraham Center of Life in San Anton...those couples, who are unable to have a biological...
... muscular dystrophy should avoid over exercising, ... or legs after exercise can be caused due to train...essional Association of Neurologists. Muscular dys... that causes progressive muscle weakness and over ...
Other Medicine News:
(Date:11/19/2008)...e/ -- Posit Science Corporation,researcher, Dan T...science,Annual Conference in Washington, DC this ...it Baby Boomers. The computerized brain plasticit...exercises that target auditory and,language syste...ed,improvements in cognition by improving speed a...
(Date:11/19/2008)... statistical significance , , ISELIN, N.J.,...ation (Nasdaq: PARS ) today announced results fr...Emulsion (NE) drug delivery technology formulated ...multi-center, randomized, double-blinded, placebo-... of the Company,s 3% Diclofenac Diethanolamine Nan...
(Date:11/19/2008)...wswire/ -- Biotech scientists increasingly are app... to better understand the effects of novel drug ca...enetic Engineering & Biotechnology News ( GEN... a new compound,s mechanism of action and eventual...ccording to the November 15 issue of GEN . ( http...
(Date:11/19/2008)... Roche- , , MONTVALE, N.J., Nov. 19 /PRNews...asdaq: MEMY ) today announced that it has achiev...487/MEM 3454, its lead alpha-7 nicotinic receptor ...chizophrenia (CIAS). The Company has randomized 2...0 million payment from its partner Roche. Memory ...
Breaking Medicine Technology:New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Skystar Bio Pharmaceutical Announces Upcoming Interview With WallSt net 28 www wallst net 29 4134 1Skystar Bio Pharmaceutical Announces Upcoming Interview With WallSt net 28 www wallst net 29 4134 2Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007 1370 1Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007 1370 2Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday November 5 2007 1368 1Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday November 5 2007 1368 2Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday November 5 2007 1368 3Xytis Names Gordon H Busenbark as Chief Financial Officer 576 1Xytis Names Gordon H Busenbark as Chief Financial Officer 576 2
...-AstraZeneca today announced clinical,trial data f...ine,fumarate sustained release), at the European C...monstrated that the SEROQUEL®,sustained releas...se), administered once daily, significantly improv...d by PANSS) and increased the,time to psychiatric ...
...NESS WIRE)--Mar 20, 2007 - Calando,Pharmaceuticals...ity-owned subsidiary of Arrowhead Research Corpora...he Proceedings of the,National Academy of Sciences... first non-human primate study to use multiple, sy...c candidate that is a,nanoparticle containing non-...
Other Medicine Technology:Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 2Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 3Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5
Zeiss offers a full range of filter sets for a variety of applications.
Dust covers for a variety of Zeiss microscopes
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark
...that offers you much more than you have ever expec...e impressed by the outstanding quality, and functi... work as easy and safe as possible thus increasin... more time for the observation. , Contrasting...
Medicine Products: